Prospective-retrospective study reveals key predictors for overall survival in mNSCLC patients treated with pembrolizumab, indicating critical clinical factors.
Key Points
The median overall survival in the real-world analysis was 29.30 months, indicating significant efficacy of pembrolizumab in advanced NSCLC.
Immune-mediated adverse events occurred in 42% of patients, with serious events noted in 12%, underscoring safety concerns.
Clinical factors like ECOG PS 2, male gender, and squamous histology are negative predictors for overall survival in this population.
Insights from this study offer valuable real-world evidence on pembrolizumab efficacy and safety for advanced NSCLC management.